Stockscreener 앱 받기
41.69
4.71%
-2.1258
전일 마감가:
$43.82
열려 있는:
$43.27
하루 거래량:
243.28K
Relative Volume:
0.15
시가총액:
$8.61B
수익:
-
순이익/손실:
$-505.61M
주가수익비율:
-15.05
EPS:
-2.7697
순현금흐름:
$-407.32M
1주 성능:
-5.89%
1개월 성능:
+7.34%
6개월 성능:
+50.58%
1년 성능:
+181.76%
1일 변동 폭
$41.64
$43.38
1주일 범위
$41.66
$44.50
52주 변동 폭
$14.47
$45.42
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
41.69 | 9.16B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
542.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.88 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.73 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant, Inc. (IMVT) Stock Analysis: Assessing the 21% Potential Upside with Strong Analyst Confidence - DirectorsTalk Interviews
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant (IMVT) Pulls Back 2.26% as Biotech Jitters Persist — $37.04 Support in FocusRating Change - Vinanet
Liquidity Mapping Around (IMVT) Price Events - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant Holds Near $40 as IMVT Consolidates Above Key SupportInverse ETF Flow - Vinanet
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Q1 2027 Earnings Call: Clinical Pipeline and Financial Outlook Take Center StageDividend Growth Analysis - vinanet.vn
Immunovant, Inc. Q1 2027 Earnings Call Summary - finance.yahoo.com
Immunovant Q1 Earnings Call Highlights - MarketBeat
Form 8K Immunovant Inc For: 6 August By Investing.com - Investing.com Nigeria
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside - TradingView
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - The Globe and Mail
Immunovant Fiscal Q1 Loss Widens - marketscreener.com
Immunovant, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss - marketscreener.com
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary - TradingView
Aug 06 (Reuters)Immunovant Q1 Operating Ex - Moomoo
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026 - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - manilatimes.net
Immunovant | 8-K: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - Moomoo
IMMUNOVANT Q1 NET INCOME USD -153.224 MILLION VS. IBES ESTIMATE USD -130.2 MILLION - Moomoo
Immunovant earnings up next as analysts eye pipeline pivot - Investing.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming DeadlineIMVT; HSACU; HSAC; and HSACW - TMX Newsfile
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00 - GuruFocus
Immunovant (NASDAQ:IMVT) Price Target Raised to $50.00 - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: Navigating a 21.72% Upside Potential in Biotech Investment - DirectorsTalk Interviews
Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT.US) will release its earnings report before the market opens on August 6. - moomoo.com
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Immunovant (IMVT) Edges Lower as Shares Test Key Support LevelsPut Flow Alert - vinanet.vn
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
Jul 24 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
| Girao Tiago | Chief Financial Officer |
Jul 23 '26 |
Sale |
38.69 |
6,798 |
263,015 |
240,798 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '26 |
Sale |
38.69 |
2,857 |
110,537 |
205,341 |
| Gloria Melanie | Chief Operating Officer |
Jul 08 '26 |
Sale |
39.55 |
2,036 |
80,532 |
222,357 |
| Van Tuyl Christopher | Chief Legal Officer |
Jul 08 '26 |
Sale |
39.55 |
1,206 |
47,702 |
179,391 |
| Stout Jay S | Chief Technology Officer |
Jul 08 '26 |
Sale |
39.55 |
3,487 |
137,925 |
208,198 |
| Venker Eric | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
14.46 |
92,188 |
1,333,038 |
344,001 |
| Venker Eric | Chief Executive Officer |
Jul 02 '26 |
Sale |
38.48 |
3,092 |
118,980 |
254,280 |
| Gloria Melanie | Chief Operating Officer |
Jun 26 '26 |
Sale |
38.31 |
17,714 |
678,604 |
224,393 |
2.38%
자본화:
|
볼륨(24시간):